RankAlpha logo
Back to Rankings

AVIR

AteaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
AVIR vs peer average
39/100
AVIR vs. peer average (D vs. C)
Grade spread
B 3 · C 3 · D 2 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

GILD is the first available peer comparator.

Direct HCV operating comparator rather than a same-market-cap peer: Atea uses sofosbuvir/velpatasvir, marketed as Epclusa by Gilead, as the active comparator in C-BEYOND, so GILD is the clearest benchmark for efficacy, safety, and commercial bar setting [#10-K-2026-03-05].

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerGILDGilead Sciences
AVIR
Atea
GILD
Gilead Sciences
Grade
D
C
Momentum
35
28
Value
41
65
Sentiment
51
56
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs GILD

AVIR / GILD
Grade Position
Below peers
AVIR vs. peer average (D vs. C)
39/100
Momentum
35
AVIR
Value
41
GILD
Sentiment
51
GILD

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs AVIR
1
GILD
GILD
C
60/100
-1
2
ABBV
ABBV
B
80/100
-2
3
AUTL
Autolus Therapeutics Plc ADR
B
80/100
-2
4
LXEO
Lexeo Therapeutics Inc Common
F
20/100
+1
5
STRO
Sutro Biopharma Inc Common
D
40/100
Even
GILD is the first peer returned for this comparison set.